|
3 Companies |
|
0 Products |
|
0 Products |
|
1 Mechanism of Action |
|
0 Trials |
|
13 News |
|
- | Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Trial completion: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jun 26, 2017
P1, N=72, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Enrollment closed, Trial primary completion date: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jan 23, 2017
P1, N=72, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
Enrollment open: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Feb 20, 2015
P1, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- ||||||| praziquantel / Generic mfg.
Trial completion: Safety and Efficacy of Mirazid for Schistosomiasis Treatment (clinicaltrials.gov) - Feb 20, 2015
P3, N=200, Completed, Sponsor: Pharco Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion, Enrollment change: TB036: Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (clinicaltrials.gov) - Jan 30, 2015
P2, N=36, Completed, Sponsor: University of Oxford
Recruiting --> Completed Recruiting --> Completed | N=90 --> 36
- Sm-TSP-2/Alhydrogel vaccine / Baylor College of Medicine, National Institutes of Health
New P1 trial: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel (clinicaltrials.gov) - Jan 15, 2015
P1, N=72, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- praziquantel / Generic mfg.
Trial completion: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Sep 19, 2014
P2, N=800, Completed, Sponsor: Makerere University
Recruiting --> Completed | N=90 --> 36 Active, not recruiting --> Completed
- | New P2 trial: TB036: Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (clinicaltrials.gov) - Jul 1, 2014
P2, N=90, Recruiting, Sponsor: University of Oxford
- ||| praziquantel / Generic mfg.
Clinical: Arachidonic Acid Treatment Against Schistosomiasis Infection in Children (clinicaltrials.gov) - May 20, 2014
P=N/A, N=335, Completed, Sponsor: DSM Nutritional Products, Inc.
- praziquantel / Generic mfg.
Enrollment closed: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Mar 24, 2014
P2, N=800, Active, not recruiting, Sponsor: Makerere University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Surgery: Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery (clinicaltrials.gov) - Aug 25, 2013
P=N/A, N=54, Completed, Sponsor: Universidade Estadual de Ci
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | praziquantel / Generic mfg.
New P2 trial: Schistosoma Mansoni Morbidity in Children Aged 1-5 Years (clinicaltrials.gov) - Jul 15, 2013
P2, N=800, Active, not recruiting, Sponsor: Makerere University
- |||||||||| praziquantel / Generic mfg.
New P3 trial: Safety and Efficacy of Mirazid for Schistosomiasis Treatment (clinicaltrials.gov) - Feb 5, 2012
P3, N=200, Recruiting, Sponsor: Pharco Pharmaceuticals